Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study

Trial Profile

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs AFM 13 (Primary)
  • Indications Lymphoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 01 Feb 2018 According to an Affimed Therapeutics media release, enrollment of the third dose cohortis ongoing.
    • 01 Feb 2018 Results from first cohort published in an Affimed Therapeutics Media Release
    • 16 Jun 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top